-
Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy
•
Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of renminbi in a Pre-Series B financing round. The round was led by Yuexiu Industrial Fund, with participation from other notable investors including Yuanying Venture Capital, Shanfeng Venture Capital, Emerging Fund, Ganyue Investment, Guoju Venture Capital,…
-
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
•
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease in turnover at constant exchange rates (CER) to CHF 15.3 billion (USD 17.2 billion) in its Q1 2023 report. The decline was attributed to the appreciation of the Swiss franc and a predicted drop in…
-
Dizal Pharma Plans to Raise $376.1 Million for Drug R&D and Industrialization
•
Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ, NASDAQ: AZN) and the state-backed Future Industry Investment Fund in October 2017, has announced plans to raise RMB 2.6 billion (USD 376.1 million) through a private placement of 40,815,137 shares. The funds raised will be…
-
Meilitech Secures Series A+ Funding Led by Autobio Diagnostics for Cancer Detection Tech
•
Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions of renminbi in a Series A+ financing round, led exclusively by Autobio Diagnostics Co., Ltd (SHA: 603658). The funds raised will be directed towards technology research and development, product iteration, and end-implementation efforts. Company Background…
-
Beijing-Based Holox Secures Tens of Millions in Series A+ Financing for Healthcare Software
•
Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The funds raised will be directed towards the research and development of new products and the globalization of the company’s operations. Company Background and Pharmaceutical Safety ServicesFounded in…
-
Shanghai Kingstar Winning Secures $43.39 Million in Series C Financing for Digital Healthcare Solutions
•
Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk control solutions for medical and commercial insurance, has reportedly raised RMB 300 million (USD 43.39 million) in a Series C financing round. The round was led by China Taiping Insurance Group Company’s healthcare funds, with…
-
CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments
•
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140 million (USD 20.3 million) in the establishment of a private equity fund with a total value of RMB 500 million (USD 72.5 million). The fund will focus on investments in vaccine companies, highlighting CanSino’s commitment…
-
PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange
•
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of Global Depositary Receipt (GDR) shares. A total of 34 million shares of common stock were offered at a price of USD 13.61 per share, resulting in a capital raise of USD 462.7 million. The shares…
-
Biosion Secures Series B+ Financing to Advance Antibody-Based Therapies Pipeline
•
Biosion, a global, clinical-stage biotech company dedicated to developing antibody-based therapies for immune and oncologic diseases, has successfully raised tens of millions of renminbi in a Series B+ financing round. The funds will be allocated to the development and advancement of the company’s innovative pipelines and to support its robust…
-
Hasten Biopharmaceutical Secures $315 Million Investment for Pipeline Expansion
•
China-based Hasten Biopharmaceutical Co., Ltd has reportedly received USD 315 million in a fundraising round co-led by CBC Group and the Abu Dhabi sovereign wealth fund Mubadala Investment Company, with participation from other unnamed institutional investors. The capital raised is intended to fund future acquisitions and deal-making focused on innovative…
-
Staidson Pharmaceutical Plans RMB 580 Million Private Placement for Drug R&D
•
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced plans to raise RMB 580 million (USD 84.1 million) through a private placement, with the net proceeds designated for innovative drug research and development (R&D). This move follows previous unsuccessful attempts to raise funds through private placements of RMB 1.08…
-
Sangon Biotech Secures RMB 2 Billion in First Financing Round to Boost Life Science Services
•
China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million) in its first financing round, led by GL Capital. Joining the round are CITIC Private Equity, Greenwoods Investment, Huagai Capital, and Guokai Technology Venture Investment. This significant funding will enable Sangon to accelerate human resource…
-
Shenzhen 01 Life Science Secures RMB 100 Million in Series B1 Financing for Microecology Platform
•
Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big data-driven microecology high-throughput screening and application transformation, has reportedly raised RMB 100 million (USD 14.5 million) in a Series B1 financing round. The investors in this round include Green Pine Capital Partners, Seas Capital, Green…
-
Ubrigene Secures RMB 150 Million in Series C+ Financing to Expand Global CGT CDMO Platform
•
Yiming Cell Biotechnology Co., Ltd, known as Ubrigene Biosciences Inc., a leading gene and cell therapy contract development and manufacturing organization (CDMO) based in Beijing, has reportedly raised RMB 150 million (USD 21.8 million) in a Series C+ financing round. The funding was led by Guotai Junan Innovation Investment and…
-
Shanghai Huikai Medical Technology Secures Series A+ Funding for Prostate Stent System
•
Shanghai Huikai Medical Technology Co., Ltd, a China-based urology device manufacturer, has reportedly raised tens of millions of renminbi in a Series A+ financing round, led exclusively by Beijing NatonTechnology Group Co., Ltd. The funds raised will be directed towards clinical studies and market promotion efforts. HuiKai Medtech’s Core Product…
-
Nanjing Chamlion Laser Technology Secures RMB 236 Million in Series B Financing for Dental 3D Printing
•
Nanjing Chamlion Laser Technology Co., Ltd, a leading provider of dental metal 3D printing solutions in China, has reportedly raised RMB 236 million (USD 34.3 million) in a Series B financing round. The round was led by 3H Health Investment, with participation from Vertex Ventures and ZhenCheng Capital. The funds…
-
PackGene Secures Series C Financing to Boost AAV Innovation and Global Expansion
•
China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing hundreds of millions of renminbi. The round was led by a consortium of investors including GDD Industry Fund, Guangzhou Xinxing Industry Development Fund, Yuegang Capital, Sanmei Investment, and Guangzhou Guoju Venture Capital, along with an…
-
Bioworkshops Secures RMB 100 Million in Series A Financing for Biologic Drug Development
•
Bioworkshops, a Contract Development and Manufacturing Organization (CDMO) based in Suzhou and specializing in biologic drugs, has announced the completion of a Series A financing round worth RMB 100 million (USD 14.5 million). The investment was led by Jiangsu Tech Industry Investment Co., Ltd. Company Background and ServicesFounded in 2019,…
-
Shenzhen Core Medical Technology Secures RMB 200 Million in Series C+ Financing for Artificial Heart Tech
•
Shenzhen Core Medical Technology Co., Ltd, a leading Chinese manufacturer of artificial hearts, has reportedly raised nearly RMB 200 million (USD 29.1 million) in a Series C+ financing round. The round was led by Loyal Valley Capital, with participation from Greenwoods Asset, highlighting the strong investor confidence in Core Medtech’s…
-
Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development
•
Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more than RMB 200 million (USD 29.1 million) in a Series B financing round. This significant investment, led by CCB Trust, will fuel the company’s efforts in advancing stem-cell drugs for a variety of diseases and…
